6th Aug 2015 08:16
LONDON (Alliance News) - Chinese pharmaceutical company Taihua PLC on Thursday said it has started the preparations required for it to renew its Chinese good manufacturing practice certificate.
As a result, all production of the company's traditional Chinese medicines, homoharringtonine and paclitaxel has been halted while its facilities are refitted to meet the rules.
It expects production of the traditional Chinese medicines to restart before the end of September, with homoharringtonine and paclitaxel production to restart by the end of the year.
Taihua said it does not expect the halt to have any immediate effect on its trading, as it has sufficient stock to fulfil its anticipated orders for the next few months while the refit work takes place.
Shares in Taihua were untraded on Thursday, having last traded at 2.58 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
TAIH.L